Viral Vector Development Service
In many cases, gene therapy requires a vector to deliver the gene therapy drug to the target cell. Viral vectors have been one of the most widely studied vectors due to their outstanding transduction efficiency and other significant advantages. Viral vector-based gene therapy has now achieved good clinical results. More than a dozen viral gene therapy products have been approved for the treatment of cancer, infectious diseases, and rare single-gene disorders. The main types of viral vectors used clinically for in vivo gene therapy include adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), retroviruses, and lentiviruses.
In recent years, scientific advances in viral vector engineering, rare disease genome identification, and gene editing are ushering in a new era of viral gene therapy. Our company is committed to using cutting-edge technologies in molecular biology and cell biology to provide comprehensive viral vector development services to our customers, including the design and construction of suitable viral vectors as well as the production and purification of viral vectors.
Fig. 1 Schematic of the structure of viral particles and organization of the viral genomes. (Schaffer D V, et al., 2008)
Our Gene Therapy Viral Vector Development Services for Rare Disease
Development of Adenoviral Vectors
We are committed to providing customers with services to develop adenoviral vectors that produce milder immune responses to deliver larger DNA packages with less risk, accelerating the development of effective gene therapies for rare diseases.
Development of Adeno-Associated Virus Vectors
We aim to better understand AAV vector gene delivery and activation of gene expression to help customers improve vector manufacturing and efficiency of AAV gene therapy and develop AAV vectors for gene therapy of rare diseases.
Development of Retroviral Vectors
We provide customers with retroviral vector development services, including the design of safer vectors, the establishment of transduction protocols, and the evaluation of the efficacy and safety of gene therapy vectors.
Development of Lentiviral Vectors
We use a variety of strategies to improve the expression and transduction efficiency of lentivirus vectors and achieve tissue or cell type specificity to help customers design and develop efficient and safe lentivirus vectors.
Development of Herpes Simplex Virus Vectors
We help customers develop HSV vectors for gene therapy of rare diseases, particularly neurological disorders, to efficiently deliver genes into the central and peripheral nervous systems.
Development of Vaccinia Viral Vectors
We are committed to providing services for the development of highly attenuated, non-replicating, or poorly replicating vaccinia virus vectors for rare disease gene therapies.
Development of Baculovirus Vectors
We provide our customers with safe and effective baculovirus vectors for gene delivery, which can help accelerate the development of gene therapies for a number of rare diseases such as Duchenne muscular dystrophy (DMD).
Development of Alphavirus Vectors
We help customers develop alphavirus vectors with reduced cytotoxicity and enhanced gene expression capacity to enable effective gene delivery in gene therapies for rare diseases.
In addition to the more common vector systems, we are also developing other viral vectors for targeted gene therapy, including measles virus vectors, foamy virus vectors, flavivirus vectors, Newcastle disease virus (NDV), picornaviruses, etc.
As a leading provider of services and products in the field of gene therapy, our company is committed to providing professional viral vector development services for basic and pre-clinical research and selecting the appropriate viral vector for your rare disease gene therapy development project. If you are interested in our services, please contact us for more information.
Reference
- Schaffer, D. V.; et al. Molecular engineering of viral gene delivery vehicles. Annu. Rev. Biomed. Eng., 2008, 10: 169-194.
For Research Use Only.
